Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction (a type of heart attack), pulmonary embolism associated with low blood pressure, and blocked central venous catheter.[5] It is given by injection into a vein or artery.[5] Alteplase is the same as the normal human plasminogen activator produced in vascular endothelial cells[6] and is synthesized via recombinant DNA technology in Chinese hamster ovary cells (CHO). Alteplase causes the breakdown of a clot by inducing fibrinolysis.[7]
It is on the World Health Organization's List of Essential Medicines.[8]
Blood flow obstructed by coagulated blood that could potentially be reversed with alteplase.
^Australian Public Assessment Report for Alteplase (AusPAR) (PDF). Therapeutic Goods Administration (TGA) (Report). February 2011.
^Cite error: The named reference Activase FDA label was invoked but never defined (see the help page).
^Cite error: The named reference Cathflo Activase FDA label was invoked but never defined (see the help page).
^"Actilyse". European Medicines Agency. 17 September 2018. Archived from the original on 17 November 2020. Retrieved 14 November 2020.
^ ab"Alteplase Monograph for Professionals". Drugs.com. Archived from the original on 27 August 2020. Retrieved 11 November 2019.
^Baskin JL, Pui CH, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, et al. (July 2009). "Management of occlusion and thrombosis associated with long-term indwelling central venous catheters". Lancet. 374 (9684): 159–69. doi:10.1016/S0140-6736(09)60220-8. PMC 2814365. PMID 19595350.
^Cite error: The named reference :6 was invoked but never defined (see the help page).
^World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic...
Management of Acute Ischemic Stroke supports considering tenecteplase over alteplase in patients without contraindication to intravenous thrombolytics. Distribution:...
medications, such as anticoagulants and thrombolytic tpA medication (such as alteplase) which can increase the bleeding risk. Effective treatment is complex...
(alteplase), but the modifications give reteplase a longer half-life of 13–16 minutes. Reteplase also binds fibrin with lower affinity than alteplase,...
manufactured using recombinant techniques and is sold as alteplase, reteplase, and tenecteplase. Alteplase was the first of these versions to go on the market...
-arit for antiarthritic agents (e.g. lobenzarit) -ase for enzymes (e.g. alteplase) -azepam or -azolam for benzodiazepines (e.g. diazepam and alprazolam)...
Vidara Therapeutics and finally Horizon Pharma as of 2019. Activase (alteplase), for heart attacks. Akynzeo (netupitant/palonosetron), for nausea and...
tissue plasminogen activator (also known as tPA, t-PA, rtPA, Activase, or Alteplase or Actilyse) in the US and other countries, and edaravone (Radicut) in...
Willebrand factor Other Biomarkers- PARK7, B-type neurotrophic growth factor. Alteplase (t-PA) is an effective medication for acute ischemic stroke. When given...
production. The thrombolytic medication against myocardial infarction alteplase (Activase) was approved by the US Food and Drug Administration in 1987...
high and therefore, treatment using streptokinase is not recommended. Alteplase is a recombinant tissue plasminogen activator which enhances the conversion...
with thrombolysis (clot dissolution) by thrombolytic medications (e.g., alteplase, reteplase), as either alternative or complement thereto. It is commonly...
medical imaging between 4.5 hours and 9 hours or who wake up with stroke, alteplase results in some benefit. Its use is endorsed by the American Heart Association...
This is achieved by the administration of a drug (such as urokinase or alteplase) that activates plasmin, an enzyme that occurs naturally in the body and...
Abbokinase) and competes with recombinant tissue plasminogen activator (e.g., alteplase) as a thrombolytic drug. All plasminogen activators (urokinase, tPA) catalyze...
KP, Hamilton S (1999). "Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study:...
requires thrombolysis or embolectomy. Thrombolysis can be systemic via IV alteplase (tPA) or catheter-directed. tPA works to break up the clot. A major risk...
prompt evaluation for acute ischemic stroke and administration of IV alteplase in conjunction with Neurology. From the onset of the COVID-19 pandemic...
Currently available thrombolytic agents include streptokinase, urokinase, and alteplase (recombinant tissue plasminogen activator, rtPA). More recently, thrombolytic...
RO, Soinne L, Toni D, Vanhooren G (January 2007). "Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis...
anti-platelet therapy like aspirin and clopidogrel, and thrombolytic therapy like alteplase and streptokinase. If an embolus is causing life or limb-threatening ischemia...
Global Information
